{"schema_version":"secwatch.filing_event.v1","accession":"0001638833-25-000132","form_type":"8-K","ticker":"SGRY","cik":"0001638833","company_name":"Surgery Partners, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.540070+00:00","generated_at":"2026-05-17T20:44:46.732823+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Surgery Partners Q2 revenue up 8.4% to $826.2M; Adj EBITDA $129M, up 9%; reaffirms FY2025 guidance","bullets":["Revenue $826.2M (+8.4% YoY); same-facility revenue +5.1%, same-facility cases +3.4%.","Adjusted EBITDA $129.0M (+9.0% YoY); net loss attributable to Surgery Partners $2.5M.","Full-year 2025 guidance reaffirmed: revenue $3.30-3.45B, Adjusted EBITDA $555-565M.","Cash $250.1M and $394.9M revolver capacity at June 30, 2025; net debt/EBITDA 4.1x.","CEO cites active evaluation of portfolio optimization to reduce leverage and accelerate cash flow."],"urls":{"canonical":"https://secwatch.observer/filing/0001638833-25-000132","json":"https://secwatch.observer/filing/0001638833-25-000132.json","markdown":"https://secwatch.observer/filing/0001638833-25-000132.md","text":"https://secwatch.observer/filing/0001638833-25-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638833/000163883325000132/0001638833-25-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638833/000163883325000132/sgry-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:44:46.732823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}